ADMA Biologics, Inc. Announces Pricing of Initial Public Offering

RAMSEY, N.J.--(BUSINESS WIRE)--ADMA Biologics, Inc. (OTCQB: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced the pricing of its initial public offering of 3,352,941 shares of its common stock at a public offering price of $8.50 per share. All of the shares of common stock are being offered by ADMA Biologics. In addition, ADMA Biologics has granted the underwriters a 30-day option to purchase up to an additional 502,941 shares of common stock at the same price to cover over-allotments, if any. The company's shares are expected to begin trading on The OTCQB Marketplace on October 17, 2013 under the ticker symbol “ADMA.”

Help employers find you! Check out all the jobs and post your resume.